Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the benzamide class. It has been identified in chemical and pharmacological databases (e.g., DrugBank as DB07316) but is not an approved drug in any jurisdiction. The primary known mechanism of action is inhibition of 11-beta-hydroxysteroid dehydrogenase 1 (11β-HSD1), an enzyme involved in glucocorticoid metabolism. Inhibition of this enzyme has been explored for potential therapeutic effects in metabolic diseases such as type 2 diabetes and obesity due to its role in regulating local cortisol levels. There are no reported clinical trials or approved indications for this compound[2].
- Other names
- N-(1-((1-carbamoylcyclopropyl)methyl)piperidin-4-yl)-N-cyclopropyl-4-((1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl)benzamide
02
Targets
HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)
Beyond the preview
Go deeper on N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide.